Europe fibrotic diseases treatment market is projected to register a substantial CAGR of 6.0%in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030. Market Segmentation: Europe Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe) Industry Trends and Forecast to 2030 Some of the major factors contributing to the growth of the Europe fibrotic diseases treatment market are: • Technological advancement in the treatment of fibrosis diseases • Increase in the number of people smoking cigarettes Market Players: Some of the key market players in the Europe fibrotic diseases treatment market are listed below: • Boehringer Ingelheim International GmbH • AbbVie Inc. • Redx Pharma Plc • Bristol-Myers Squibb Company • Gilead Sciences, Inc. • KITHER BIOTECH S.R.L. • Verona Pharma plc • Intercept Pharmaceuticals, Inc. • Pharmaxis Ltd. • Teva Pharmaceutical Industries Ltd. • Sandoz International GmbH

1 INTRODUCTION 33 1.1 OBJECTIVES OF THE STUDY 33 1.2 MARKET DEFINITION 33 1.3 OVERVIEW OF THE EUROPE FIBROTIC DISEASES TREATMENT MARKET 33 1.4 LIMITATIONS 35 1.5 MARKETS COVERED 35 2 MARKET SEGMENTATION 37 2.1 MARKETS COVERED 37 2.2 GEOGRAPHICAL SCOPE 38 2.3 YEARS CONSIDERED FOR THE STUDY 39 2.4 CURRENCY AND PRICING 39 2.5 DBMR TRIPOD DATA VALIDATION MODEL 40 2.6 MULTIVARIATE MODELLING 43 2.7 TREATMENT TYPE LIFELINE CURVE 43 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44 2.9 DBMR MARKET POSITION GRID 45 2.10 MARKET END USER COVERAGE GRID 46 2.11 VENDOR SHARE ANALYSIS 47 2.12 SECONDARY SOURCES 48 2.13 ASSUMPTIONS 48 3 EXECUTIVE SUMMARY 49 4 PREMIUM INSIGHTS 51 4.1 PORTER'S 5 FORCES 52 4.2 PESTEL ANALYSIS 53 5 EPIDEMIOLOGY 54 5.1 INCIDENCE OF ALL BY GENDER 54 5.2 TREATMENT RATE 54 5.3 MORTALITY RATE 54 5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55 5.5 PATIENT TREATMENT SUCCESS RATE 55 6 INDUSTRY INSIGHTS 56 6.1 PATENT ANALYSIS 56 6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56 6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56 6.4 KEY PRICING STRATEGIES 57 6.5 KEY PATIENT ENROLLMENT STRATEGIES 58 7 MERGERS AND ACQUISITIONS 60 7.1 LICENSING: 60 7.2 COMMERCIALIZATION AGREEMENTS 60 8 PIPELINE ANALYSIS 61 8.1 PHASE 1 61 8.2 PHASE 2 61 8.3 PHASE 3 61 9 EUROPE FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62 9.1 FDA APPROVALS 62 9.2 EMA APPROVALS 63 10 MARKET OVERVIEW 64 10.1 DRIVERS 66 10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66 10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66 10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67 10.2 RESTRAINTS 67 10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67 10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67 10.3 OPPORTUNITIES 68 10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68 10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68 10.4 CHALLENGES 69 10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69 10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69 11 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70 11.1 OVERVIEW 71 11.2 MEDICATION 73 11.2.1 INTEDANIB (OFEV) 74 11.2.2 PIRFENIDONE (ESBRIET) 74 11.3 ORGAN TRANSPLANTATION 74 11.4 OXYGEN THERAPY 75 11.5 OTHERS 76 12 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77 12.1 OVERVIEW 78 12.2 IDIOPATHIC PULMONARY FIBROSIS 81 12.3 HEPATIC CIRRHOSIS 81 12.4 RENAL FIBROSIS 82 12.5 CUTANEOUS FIBROSIS 83 12.6 OTHERS 84 13 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85 13.1 OVERVIEW 86 13.2 HOSPITALS 89 13.3 SPECIALTY CLINICS 90 13.4 ACADEMIC AND RESEARCH INSTITUTES 90 13.5 OTHERS 91 14 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92 14.1 OVERVIEW 93 14.2 HOSPITAL PHARMACY 96 14.3 RETAIL PHARMACY 96 14.4 OTHERS 97 15 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98 15.1 EUROPE 99 15.1.1 GERMANY 106 15.1.2 FRANCE 108 15.1.3 U.K. 110 15.1.4 ITALY 112 15.1.5 SPAIN 114 15.1.6 RUSSIA 116 15.1.7 TURKEY 118 15.1.8 NETHERLANDS 120 15.1.9 SWITZERLAND 122 15.1.10 HUNGARY 124 15.1.11 LITHUANIA 126 15.1.12 AUSTRIA 128 15.1.13 IRELAND 130 15.1.14 NORWAY 132 15.1.15 POLAND 134 15.1.16 REST OF EUROPE 136 16 EUROPE FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 137 16.1 COMPANY SHARE ANALYSIS: EUROPE 137 17 SWOT ANALYSIS 138 18 COMPANY PROFILE 139 18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 139 18.1.1 COMPANY SNAPSHOT 139 18.1.2 REVENUE ANALYSIS 139 18.1.3 COMPANY SHARE ANALYSIS 140 18.1.4 PRODUCT PORTFOLIO 140 18.1.5 RECENT DEVELOPMENTS 140 18.2 GENENTECH, INC. 141 18.2.1 COMPANY SNAPSHOT 141 18.2.2 COMPANY SHARE ANALYSIS 141 18.2.3 PRODUCT PORTFOLIO 142 18.2.4 RECENT DEVELOPMENTS 142 18.3 SANDOZ INTERNATIONAL GMBH 143 18.3.1 COMPANY SNAPSHOT 143 18.3.2 COMPANY SHARE ANALYSIS 143 18.3.3 PRODUCT PORTFOLIO 144 18.3.4 RECENT DEVELOPMENTS 144 18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 145 18.4.1 COMPANY SNAPSHOT 145 18.4.2 REVENUE ANALYSIS 145 18.4.3 COMPANY SHARE ANALYSIS 146 18.4.4 PRODUCT PORTFOLIO 146 18.4.5 RECENT DEVELOPMENTS 146 18.5 ACCORD HEALTHCARE U.S. 147 18.5.1 COMPANY SNAPSHOT 147 18.5.2 COMPANY SHARE ANALYSIS 147 18.5.3 PRODUCT PORTFOLIO 148 18.5.4 RECENT DEVELOPMENTS 148 18.6 ABBVIE INC. 149 18.6.1 COMPANY SNAPSHOT 149 18.6.2 REVENUE ANALYSIS 149 18.6.3 PRODUCT PORTFOLIO 150 18.6.4 RECENT DEVELOPMENTS 150 18.7 ALPINE IMMUNE SCIENCES 151 18.7.1 COMPANY SNAPSHOT 151 18.7.2 REVENUE ANALYSIS 151 18.7.3 PRODUCT PORTFOLIO 152 18.7.4 RECENT DEVELOPMENTS 152 18.8 BELLBROOK LABS 153 18.8.1 COMPANY SNAPSHOT 153 18.8.2 PRODUCT PORTFOLIO 153 18.8.3 RECENT DEVELOPMENTS 153 18.9 BIOMX 154 18.9.1 COMPANY SNAPSHOT 154 18.9.2 REVENUE ANALYSIS 154 18.9.3 PRODUCT PORTFOLIO 155 18.9.4 RECENT DEVELOPMENTS 155 18.10 BRISTOL-MYERS SQUIBB COMPANY 156 18.10.1 COMPANY SNAPSHOT 156 18.10.2 REVENUE ANALYSIS 156 18.10.3 PRODUCT PORTFOLIO 157 18.10.4 RECENT DEVELOPMENTS 157 18.11 CAMBER PHARMACEUTICALS, INC. 158 18.11.1 COMPANY SNAPSHOT 158 18.11.2 PRODUCT PORTFOLIO 158 18.11.3 RECENT DEVELOPMENTS 158 18.12 ENVEDA 159 18.12.1 COMPANY SNAPSHOT 159 18.12.2 PRODUCT PORTFOLIO 159 18.12.3 RECENT DEVELOPMENTS 159 18.13 GILEAD SCIENCES, INC. 160 18.13.1 COMPANY SNAPSHOT 160 18.13.2 REVENUE ANALYSIS 160 18.13.3 PRODUCT PORTFOLIO 161 18.13.4 RECENT DEVELOPMENTS 161 18.14 INTERCEPT PHARMACEUTICALS, INC. 162 18.14.1 COMPANY SNAPSHOT 162 18.14.2 REVENUE ANALYSIS 162 18.14.3 PRODUCT PORTFOLIO 163 18.14.4 RECENT DEVELOPMENTS 163 18.15 KITHER BIOTECH S.R.L. 164 18.15.1 COMPANY SNAPSHOT 164 18.15.2 PRODUCT PORTFOLIO 164 18.15.3 RECENT DEVELOPMENTS 164 18.16 PHARMAXIS LTD 165 18.16.1 COMPANY SNAPSHOT 165 18.16.2 REVENUE ANALYSIS 165 18.16.3 PRODUCT PORTFOLIO 166 18.16.4 RECENT DEVELOPMENTS 166 18.17 REDX PHARMA PLC. 167 18.17.1 COMPANY SNAPSHOT 167 18.17.2 REVENUE ANALYSIS 167 18.17.3 PRODUCT PORTFOLIO 168 18.17.4 RECENT DEVELOPMENTS 168 18.18 VERONA PHARMA PLC 169 18.18.1 COMPANY SNAPSHOT 169 18.18.2 REVENUE ANALYSIS 169 18.18.3 PRODUCT PORTFOLIO 170 18.18.4 RECENT DEVELOPMENTS 170 19 QUESTIONNAIRE 171 20 RELATED REPORTS 174